Current leaders to maintain dominance in acute ischemic stroke, says report
Roche (ROG: SIX) and Boehringer Ingelheim’s Activase (alteplase) is currently the only treatment of acute ischemic stroke (AIS), but this situation will start to change from 2021, according to GlobalData.
The data and analytics company has published a report predicting that drugs designed to improve clinical outcomes of AIS patients will start launching from 2021, which along with the increasing prevalence of AIS, will fuel AIS market growth.
GlobalData’s report, Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027, states that the AIS pipeline is fairly strong, comprising of around 36 pipeline candidates under development including neuroprotective agents (44%), stem cell therapies (14%), and drugs for stroke recovery (11%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze